News
-
Avalyn’s New Twist on Older Lung Disease Drugs Attracts $175M for Clinical Trials
Avalyn Pharma aims to improve treatment of idiopathic pulmonary fibrosis with inhalable versions of two older oral drugs and it’s now headed for mid-stage testing backed by a Series C financing. Other recent biotech industry financings raised money for research in cancer, immunology, and rare genetic diseases.
-
MedCity Influencers, Devices & Diagnostics
Medtech Manufacturers Thrive While Hospitals Shutter—and Patients Suffer. Here’s What Needs to Be Done
Right now, manufacturers are thriving. Hospitals are failing. And patients are suffering. We must stop this trend in its tracks by becoming better stewards of hospital resources and supply chains.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Structure Raises $300M as Oral GLP-1 Drug’s Data Keep Up With Pfizer, Eli Lilly
Preliminary weight loss and safety data for Structure Therapeutics’ drug candidate suggest it’s competitive with other oral GLP-1 targeting contenders from big pharma companies. The data are from a small study and a short time frame, but Structure was able to leverage the encouraging preliminary results into a private placement of securities.
-
Midi Health Snags $25M Led by Google Ventures
Midi Health’s Series A funding round was led by Google Ventures. In total, Midi Health has raised $40 million, including from Felicis, Semper Virens, Icon, 25M and Operator Collective. The company offers virtual care for those going through perimenopause or menopause.
-
Ophelia, Vori Health Team Up To Support Patients with Opioid Addiction, MSK Pain
Through a new partnership, Vori Health will be able to refer its patients who report having an opioid addiction to Ophelia. On the flip side, Ophelia can refer its patients who report having MSK pain to Vori Health for non-opioid treatment.
-
Amicus Therapeutics Rare Disease Combo Therapy Wins Long-Awaited FDA Nod
Sanofi dominates the market for therapies that treat Pompe disease, a rare enzyme deficiency. The FDA has approved an Amicus Therapeutics combination treatment for patients inadequately served by the Sanofi products.
-
Consumer / Employer, Devices & Diagnostics, Health Tech
Healthcare Moves: A Monthly Summary of Hires and Layoffs
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
-
MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Chris Allen, CFO at Keck Medicine of USC
For the September episode, we discuss some recent executive appointments occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Chris Allen, who recently became CFO at Keck Medicine of USC.
-
BrainStorm’s ALS Data Fail to Persuade FDA Advisors, Who Vote Down the Stem Cell Therapy
NurOwn, BrainStorm Cell Therapeutics’ experimental stem cell therapy for ALS, did not win the backing of an independent panel of FDA advisors. Many advisory committee members said they want to see more data from another clinical trial, the same guidance the FDA has given the biotech for nearly three years.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
Transcarent Partners With 10 Health Systems To Launch Provider Network
Transcarent announced a new provider network, which seeks to help its employer customers provide their staff with access to high-quality, affordable care. The network includes 10 health systems — including Mount Sinai, Mass General Brigham and Intermountain Health.
-
Cartwheel Snags $20M For School-based Mental Health Services
Cartwheel, a startup that partners with school districts to provide virtual mental health services, raised $20 million in Series A funds. The company is working with about 50 school districts and charter school networks across Massachusetts, Illinois, New York, Rhode Island and Connecticut.
-
Ionis Posts Trial Data in Rare Disease That Position It to Finally Set Out on Its Own
Ionis Pharmaceuticals’ olezarsen has Phase 3 results showing the therapy handily beat a placebo at reducing fat levels in the blood due to a rare, inherited metabolic disorder with no FDA-approved drugs. Ionis plans early 2024 submissions for what could become the first medicine it commercializes without a partner.
-
Consumer / Employer, Health Tech
Costco Takes On Healthcare, Though Differently From Other Retailers, Experts Say
Costco is partnering with Sesame to offer Costco Members discounted pricing on virtual health services, including primary care and mental health. But the move is a little different from other retailers like CVS Health and Walgreens.
-
After NASH Hopes Are Dashed, Intercept Pharma Agrees to $794M Buyout
Intercept Pharmaceuticals’ acquisition by Alfasigma comes three months after the FDA again rejected the biotech’s drug as a treatment for the fatty liver disease NASH. But Intercept still has rare liver disease assets, and Italy-based Alfasigma says acquiring the company will help it expand in gastroenterology and hepatology.
-
Intermountain CEO: You Don’t Have To Be a Payvider to Reach Scale in VBC
The advancement of value-based care cannot and should not exist solely in a payvider model, Intermountain Health CEO Rob Allen argued in an interview last week. Having its own health plan made things “a little easier” when Intermountain began getting serious about at-risk contracts, but achieving success in value-based care “is more about your commitment to the approach” and forging strong relationships with payers of all types.
-
Digital Therapeutics: A Panacea for Care or Overvalued Health Tech?
Digital therapeutics will be one of the topics discussed at INVEST Digital Health scheduled for October 26 at Health Wildcatters headquarters in Pegasus Park in Dallas. Register today!
-
Pharma, Artificial Intelligence, BioPharma
Novo Nordisk Turns to Flagship’s Valo Health for AI-Driven Cardio Drug R&D
Novo Nordisk is paying Valo Health $60 million up front to gain three preclinical cardiovascular disease programs. Milestone payments for those programs and others covered under the artificial intelligence drug discovery pact could reach up to $2.7 billion.
-
Contamination Risk Sparks a Recall of GSK, Scynexis Antifungal Drug
Scynexis said no adverse events or contamination problems have been reported for Brexafemme, an antifungal approved for treating vaginal yeast infections. The biotech said the risk of cross-contamination stems from the processes of the small molecule’s third-party manufacturer.
Promoted
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
